




RealRate

PHARMACEUTICAL 2017

IMMUNE DESIGN CORP.
Rank 153 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2017

IMMUNE DESIGN CORP. Rank 153 of 313

The relative strengths and weaknesses of IMMUNE DESIGN CORP. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUNE DESIGN CORP. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 199% points. The greatest weakness of IMMUNE DESIGN CORP. is the variable Research and Development, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is -170%, being 246% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	114,081
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,263
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	660
Other Expenses	481
Other Liabilities	0
Other Net Income	0
Property and Equipment	414
Research and Development	45,134
Revenues	13,260
Selling, General and Administrative Expense	21,859

Output Variable	Value in 1000 USD
Assets	114,495
Liabilities	19,263
Expenses	67,474
Stockholders Equity	95,232
Net Income	-54,214
Comprehensive Net Income	-53,884
Economic Capital Ratio	-170%

